glp-1 consumer trends news Retailers across the country are noticing a spike in returns of clothing as more Americans embrace drugs for weight loss. The rate of retail exchanges where shoppers traded clothing for a GLP-1 Agonists Market Exclusive Research

Adv Ther (2017) 34(8):1791814

8.4 Tolerability and Real-World Adherence Gastrointestinal adverse events drive treatment discontinuation in clinical trials

Customer support leans on chatbots, which can be frustrating

Always discuss genetic findings, test results, symptoms, and treatment decisions with your healthcare provider or an allergist to determine appropriate care for your situation

Disclosures: Mary Ellen Mackesy-Amiti: Nothing to Disclose, Alexander Gutfraind: Nothing to Disclose, Eric Tatara: Nothing to Disclose, Nicholson Collier: Nothing to Disclose, Scott Cotler: Nothing to Disclose, Kimberly Page: Nothing to Disclose, Jonathan Ozik: Nothing to Disclose, Basmattee Boodram: Nothing to Disclose, Marian Major: Nothing to Disclose, Harel Dahari: Nothing to Disclose 556 BEMNIFOSBUVIR POSES HIGH BARRIER FOR RESISTANCE IN BOTH PRECLINICAL AND PHASE 1B MONOTHERAPY STUDIES Qi Huang 1 Dawei Cai 1 Shannan Lynch 1 Keith Pietropaolo 1 Xiao-Jian Zhou 1 Nancy Agrawal 1 Jean-Pierre Sommadossi 2 , 1 Atea Pharmaceuticals, Inc., 2 Atea Pharmaceuticals, Inc Background: Bemnifosbuvir (BEM), an oral prodrug of a guanosine analog, has potent pan-genotypic, best-in-class in vitro and clinical antiviral activities against all HCV genotypes tested

Food and Drug Administration for authorization to prescribe their products to treat obesity, Al-Aly said